NEW YORK (GenomeWeb) – HTG Molecular Diagnostics reported after the close of the market Tuesday that its third quarter revenues grew more than four-fold year over year amid a sharp increase in revenues from its pharmaceutical partners.

For the three-month period ended Sept. 30, HTG's total revenues climbed to $3.7 million from $913,901 in the same period a year earlier. Third quarter service revenues rose to $3.1 million from $407,836, with collaboration agreement revenue from pharma clinical programs accounting for $2.1 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

May
22
Sponsored by
Thermo Fisher Scientific

In this webinar, the third in the “New Frontiers in Liquid Biopsy Research” series, Dr. Liya Xu of the University of Southern California Michelson Center for Convergent Biosciences will discuss her team’s work using liquid biopsy technology for breast cancer research.

Jun
05

This webinar will discuss how Sanofi used literature mining to annotate the association of human leukocyte antigen (HLA) alleles with diseases and drug hypersensitivity as part of a multiple sclerosis (MS) biomarker discovery project.

Jun
14

This webinar will discuss an effort underway at the University of North Carolina Medical Center's to overcome limitations in the hematological genomic testing workflow with artificial intelligence (AI) from Sophia Genetics.

Jun
19

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.